Piper Sandler raised the price target for the Procept BioRobotics Corp (NASDAQ:PRCT) stock to “an Overweight”. The rating was released on August 11, 2023, according to finviz. The stock was initiated by Truist, who disclosed in a research note on October 25, 2022, to Buy and set the price objective to $58. In their research brief published September 02, 2022, Wells Fargo analysts initiated the Procept BioRobotics Corp stock to Overweight with a price target of $49.
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated -9.73% within the last five trades and 4.44% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 35.17% in the last 6 months and 20.36% was added to its value over the previous 3 months. PRCT stock is trading at a margin of -5.58%, -4.59% and 26.40% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Sponsored
As of the close of trading, PRCT deals in the Healthcare domain. The stock is trading -18.99 percent below its 52-week high and 151.23 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 64.36. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Procept BioRobotics Corp’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at -69.37 percent and the profit margin is -66.12 percent, and the company has reported a gross margin of 50.90 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $3.21 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 20.52 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 12.14, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 5.88 percent of Procept BioRobotics Corp shares are owned by insiders, and 82.85 percent are held by financial institutions. Nouri Alaleh, the EVP, CLO, CORP. SEC. at Procept BioRobotics Corp (PRCT) has sold 10,000 shares of firm on Jun 17 ’24 at a price of $62.18 against the total amount of $0.62 million. In another inside trade, Shiblaq Hisham, EVP, Chief Comm. Officer of Procept BioRobotics Corp (NASDAQ:PRCT) sold 26,046 shares of the firm on Jun 10 ’24 for a total worth of $1.78 million at a price of $68.24. An inside trade which took place on May 03 ’24, EVP, CLO, CORP. SEC. of Procept BioRobotics Corp Nouri Alaleh sold 30,432 shares of firm against total price of $1.92 million at the cost of $62.97 per share.
